TL;DR
This study reveals that a failure in cardiomyocyte cell division (cytokinesis) contributes to heart failure in infants with Tetralogy of Fallot with Pulmonary Stenosis (ToF/PS). They identified that this failure is linked to the gene ECT2 and regulated by beta-adrenergic receptors (β-ARs). Importantly, using a β-blocker (propranolol) to modulate β-AR signaling in neonatal mice increased cardiomyocyte division, improved heart function after injury, and suggests a potential therapeutic strategy for CHD patients.
What Problem Does This Paper Address?
Congenital Heart Disease (CHD) affects millions, and a significant long-term risk for these patients is heart failure. Current understanding of heart failure mechanisms doesn't fully address the unique challenges faced by CHD patients. This paper focuses on Tetralogy of Fallot with Pulmonary Stenosis (ToF/PS), a common CHD, and investigates how it might impact the growth and development of heart muscle cells (cardiomyocytes). Specifically, it explores whether problems with cardiomyocyte division, a process crucial for building the heart muscle, contribute to the long-term heart problems seen in ToF/PS patients.
Methods
The researchers employed a multi-pronged approach:
- Isotope Labeling (15N-thymidine): To track cell division in a ToF/PS infant, they used isotope-labeled thymidine. This allowed them to see if cells were actively dividing and incorporating new DNA.
- Single-Cell Transcriptional Profiling: This powerful technique allowed them to analyze the gene expression of individual cardiomyocytes. By comparing cycling and non-cycling cells, they could pinpoint specific genes and pathways involved in cell division failure.
- Gene Manipulation (Knockout and Overexpression): They used genetic engineering in mice to either inactivate (knockout) or increase the expression of key genes (like Ect2 and β-AR genes) to understand their role in cardiomyocyte division.
- Pharmacological Interventions: They used drugs like propranolol (a β-blocker) and forskolin to manipulate β-AR signaling and observe its effects on cardiomyocyte division.
- Live Cell Imaging: This allowed them to directly visualize the process of cytokinesis (cell division) in real-time, observing events like cleavage furrow formation and regression.
- Echocardiography and Cardiac MRI: These imaging techniques were used to assess heart function, structure, and the extent of damage after induced myocardial infarction in mice.
- Immunohistology and Immunocytology: These techniques were used to visualize specific proteins and cellular structures within heart tissue and cultured cells.
Datasets
- Human Infant Heart Samples: Samples were obtained from infants with ToF/PS and from infants without heart disease for comparative analysis.
- Fetal Human Heart Samples: Used for comparative analysis of cardiomyocyte behavior.
- Neonatal Rat Ventricular Cardiomyocytes (NRVMs): Used for in vitro studies of cytokinesis.
- Transgenic Mouse Models: Various mouse lines were used, including those with fluorescent reporters for cell cycle tracking (mAG-hGeminin, FUCCI), and genetically modified mice with inactivated Ect2 or β-AR genes.
Key Insights and Ideas
- Cytokinesis Failure as a Core Problem in ToF/PS: The most striking finding is that ToF/PS infants exhibit a significant failure in cardiomyocyte cytokinesis, leading to an increased proportion of multinucleated cells. This isn't a surgical artifact but occurs early in life.
- ECT2 is the Key Molecular Player: Single-cell profiling identified the Rho guanine nucleotide exchange factor ECT2 as a critical gene whose expression is repressed in cycling cardiomyocytes of ToF/PS patients and neonatal mice. Lowering ECT2 directly leads to cytokinesis failure.
- β-Adrenergic Receptors (β-ARs) are the Regulators: The study establishes a clear link between β-AR signaling and ECT2 regulation. Overactive β-AR signaling, common in CHD, leads to ECT2 repression and thus cytokinesis failure.
- Propranolol as a Potential Therapeutic: The ability of propranolol (a β-blocker) to reverse cytokinesis failure, increase cardiomyocyte endowment, and improve cardiac function after injury in mice is a major breakthrough. This suggests a potential therapeutic avenue for improving heart health in CHD patients.
- Cytokinesis Failure vs. Cell Cycle Entry: The research clarifies that cytokinesis failure is a distinct process from cell cycle entry. Forcing cytokinesis failure doesn't prevent cells from entering the cell cycle, but rather leads to the formation of multinucleated cells.
Key Results
- Increased Binucleation in ToF/PS: Infants with ToF/PS showed a significantly increased percentage of binucleated cardiomyocytes (50-60%) compared to healthy controls (around 20% at birth, increasing to 20% by 6 months).
- ECT2 Repression: Cycling cardiomyocytes from ToF/PS infants and neonatal mice showed significantly lower Ect2 mRNA levels.
- ECT2 Knockout Lethality: Inactivation of Ect2 in mice led to a 50% reduction in cardiomyocyte endowment, severe myocardial dysfunction, and lethality before postnatal day 2.
- β-AR Blockade Improves Endowment: Administration of propranolol to neonatal mice increased cardiomyocyte endowment by 22-30% and reduced binucleation.
- Propranolol Rescues ToF/PS Cardiomyocytes: In cultured human fetal cardiomyocytes and ToF/PS patient-derived cardiomyocytes, propranolol treatment reversed cytokinesis failure.
- Improved Cardiac Function Post-MI: Mice treated with propranolol neonatally showed significantly improved ejection fraction (42% vs. 18%) and reduced adverse remodeling after induced myocardial infarction in adulthood.
Limitations and Future Work
- Duration of Propranolol Treatment: While the study showed effectiveness with propranolol treatment from P1 to P8 in mice, the optimal timing and duration for human infants with CHD remain to be determined. The paper suggests that the first 6 months after birth might be the most critical period.
- Broader Applicability to Other CHDs: The study focused on ToF/PS. Future work should investigate if similar mechanisms are at play in other types of CHD.
- Long-term Effects in Humans: While promising, the findings in mice need to be translated to human clinical trials to confirm the safety and efficacy of β-blockers for increasing cardiomyocyte endowment in CHD patients.
- Mechanisms of β-AR Regulation of ECT2: While the link is established, the precise molecular cascade by which β-AR signaling impacts ECT2 transcription could be further elucidated.
- Potential for Uncontrolled Proliferation: The paper notes that while targeting cytokinesis is a viable strategy, interventions to stimulate cardiomyocyte cell cycle entry in adults have been associated with risks of uncontrolled proliferation. This highlights the importance of precisely targeting the final stages of cell division.
Summary updated